Rinfabate
Alternative Names: Recombinant human insulin-like growth factor-binding protein-3; rhIGFBP-3Latest Information Update: 02 Oct 2021
At a glance
- Originator Insmed
- Class Antineoplastics; Proteins
- Mechanism of Action Growth modulators; Insulin-like growth factor I modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 27 Jul 2017 Discontinued - Phase-I for Solid tumours in USA (IV)
- 09 Nov 2010 No development reported - Phase-I for Solid tumours in USA (IV)
- 02 Apr 2008 This compound is still available for licensing